Using 2022 and 2023 data on prescription drug plan (PDP) lives and the PBMs used by insurers to manage them, this paper presents a descriptive analysis of PBM markets.

Press Release | AMA analysis that adds to growing concern over anticompetitive harm resulting from low competition and high vertical integration in the PBM industry.

While existing proposals to regulate pharmacy benefit managers (PBMs) are discussed on a bipartisan basis in Washington, some experts argue that more needs to be done. Specifically, experts argue that PBMs, especially the “Big 3,” have the resources to work around legislation if it is not comprehensive.

After a decade-long case, Caremark, CVS Health’s PBM, has been ordered to pay the U.S. Government $95 million due to years of charging more than the allowable price for Medicare prescription drugs.

New York passed a package of health-related bills in an effort to improve health care access and reduce costs amidst federal cuts in healthcare spending. The package included the New York State Affordable Drug Manufacturing Act (S.1618) and legislation that establishes a state-based wholesale prescription drug program (S.371), among others initiatives.

An ongoing database maintained by the National Academy for State Health Policy outlining active state-level legislation aimed at increasing transparency around drug pricing and lowering costs.